TY - JOUR
T1 - Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
T2 - Results of a prospective, randomized phase III trial
AU - Dancey, Janet
AU - Shepherd, Frances A.
AU - Gralla, Richard J.
AU - Kim, Yong S.
N1 - Funding Information:
This trial was supported by Aventis Pharma, Bridgewater, New Jersey, USA.
PY - 2004/2
Y1 - 2004/2
N2 - Purpose and methods: Docetaxel second-line chemotherapy for non-small-cell lung cancer (NSCLC) has previously been shown to improve survival significantly compared with best supportive care (BSC). This multicenter phase III trial prospectively investigated quality of life (QOL) in NSCLC patients treated with either second-line docetaxel or BSC. Patients with stage IIIB/IV NSCLC, performance status ≤2, and adequate biochemistry and hematology were eligible if they had received ≥1 platinum-based chemotherapy regimens. Patients were randomized to docetaxel 100mg/m2 (n=49) or, after protocol amendment, to docetaxel 75mg/m2 (n=55), or to BSC (n=100), with Lung Cancer Symptom Scale (LCSS) and/or QLQ-C30 (with LC13 module) assessment every 3 weeks. Results: Longitudinal analysis including all available assessments over time showed statistically significant differences in patient-rated pain scores in favor of docetaxel overall (P=0.005) or docetaxel 100mg/m2 (P=0.003) compared to BSC. Trends in favor of docetaxel were noted on observer-rated scales for fatigue and pain for all docetaxel patients, and for total LCSS score, appetite and fatigue with docetaxel 100mg/m2. Changes from baseline to the last available assessment (end point) showed significantly (P<0.05) less deterioration in LCSS pain score in patients with docetaxel (75 and 100mg/m2 combined) than with BSC. An improved mean pain score with docetaxel 100mg/m2 was contrasted with a deterioration in mean pain score with BSC (P<0.01). There was also significantly less deterioration in the global QOL today score with docetaxel 100mg/m2 (P<0.01). Similar trends were recorded with QLQ-C30 assessments. Conclusions: Second-line docetaxel therapy for advanced NSCLC significantly improves survival with a trend towards less deterioration in QOL compared with BSC.
AB - Purpose and methods: Docetaxel second-line chemotherapy for non-small-cell lung cancer (NSCLC) has previously been shown to improve survival significantly compared with best supportive care (BSC). This multicenter phase III trial prospectively investigated quality of life (QOL) in NSCLC patients treated with either second-line docetaxel or BSC. Patients with stage IIIB/IV NSCLC, performance status ≤2, and adequate biochemistry and hematology were eligible if they had received ≥1 platinum-based chemotherapy regimens. Patients were randomized to docetaxel 100mg/m2 (n=49) or, after protocol amendment, to docetaxel 75mg/m2 (n=55), or to BSC (n=100), with Lung Cancer Symptom Scale (LCSS) and/or QLQ-C30 (with LC13 module) assessment every 3 weeks. Results: Longitudinal analysis including all available assessments over time showed statistically significant differences in patient-rated pain scores in favor of docetaxel overall (P=0.005) or docetaxel 100mg/m2 (P=0.003) compared to BSC. Trends in favor of docetaxel were noted on observer-rated scales for fatigue and pain for all docetaxel patients, and for total LCSS score, appetite and fatigue with docetaxel 100mg/m2. Changes from baseline to the last available assessment (end point) showed significantly (P<0.05) less deterioration in LCSS pain score in patients with docetaxel (75 and 100mg/m2 combined) than with BSC. An improved mean pain score with docetaxel 100mg/m2 was contrasted with a deterioration in mean pain score with BSC (P<0.01). There was also significantly less deterioration in the global QOL today score with docetaxel 100mg/m2 (P<0.01). Similar trends were recorded with QLQ-C30 assessments. Conclusions: Second-line docetaxel therapy for advanced NSCLC significantly improves survival with a trend towards less deterioration in QOL compared with BSC.
KW - Best supportive care
KW - Docetaxel
KW - Non-small-cell lung cancer
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=1642575171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642575171&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2003.09.001
DO - 10.1016/j.lungcan.2003.09.001
M3 - Article
C2 - 14739039
AN - SCOPUS:1642575171
SN - 0169-5002
VL - 43
SP - 183
EP - 194
JO - Lung Cancer
JF - Lung Cancer
IS - 2
ER -
